	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:15:48 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2005 HIGHEST RN 849400-77-7
DICTIONARY FILE UPDATES: 27 APR 2005 HIGHEST RN 849400-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10659094b.str



chain nodes :
10 11 23 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
3-25 7-10 8-11 10-12 13-17 25-26 26-27 26-28

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-16 13-14 14-15 15-16
17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
3-25 5-7 6-9 7-8 8-9 8-11 12-13 12-16 13-14 13-17 14-15 15-16 25-26
26-27 26-28
exact bonds :
7-10 10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:16:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

```
=> s l1 full
FULL SEARCH INITIATED 10:16:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    306 TO ITERATE

100.0% PROCESSED     306 ITERATIONS                                  2 ANSWERS
SEARCH TIME: 00.00.01

L3            2 SEA SSS FUL L1

=> d ibib abs hitstr tot
'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats.  The predefined substance formats
are:  (RN = CAS Registry Number)

REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN

CALC   - Table of calculated properties
EPROP  - Table of experimental properties
PROP   - EPROP and CALC

Any CA File format may be combined with any substance format to
obtain CA references citing the substance.  The substance formats
must be cited first.  The CA File predefined formats are:

ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.
```

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 10:16:28 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2005 VOL 142 ISS 18
FILE LAST UPDATED: 27 Apr 2005 (20050427/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:716271 CAPLUS
DOCUMENT NUMBER: 137:232554
TITLE: Compounds derived from oxindoles with activity as inhibitors of tubulin polymerization, and the use thereof in cancerology
INVENTOR(S): Combeau, Cecile; Mailliet, Patrick; Chiron, Marielle
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072575	A1	20020919	WO 2002-FR852	20020311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2822155	A1	20020920	FR 2001-3408	20010313
FR 2822155	B1	20031212		
EP 1370555	A1	20031217	EP 2002-722330	20020311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004082645	A1	20040429	US 2003-659094	20030910
PRIORITY APPLN. INFO.:			FR 2001-3408 A	20010313
			WO 2002-FR852 W	20020311

OTHER SOURCE(S): CASREACT 137:232554; MARPAT 137:232554
GI



I

AB The invention relates to compds. I [wherein: R5 = -NHCOR2 or -CONHR2; R2 =

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

C1-3 alkyl; X = Cl, Br; n = 1-3; exocyclic double bond is E, Z, or a mixt.]. I have antimitotic, antiproliferative, and antivascular properties by inhibition of the polymn. of tubulin into microtubules. Three specific compds. were prepd. in examples and claimed. For instance, condensation of 5-(acetylamino)indolin-2-one with N-(3,5-dichlorophenyl)pyrrole-2-carboxaldehyde in the presence of piperidine in refluxing EtOH gave I [R5 = NHCOMe; (X)n = 3,5-dichloro] (II) in 40% yield. This compd. inhibited the polymn. of porcine cerebral tubulin in vitro with an IC50 of 2.4 μM. II also inhibited proliferation of HeLa cells in vitro with an IC50 of 0.05 μM, and induced detachment of HDMEC cells in vitro by 29% at 1 μM.

IT **459143-84-1P**, 3-[[N-(3,5-Dichlorophenyl)pyrrol-2-yl]methylene]-5-(acetylamino)indolin-2-one **459143-85-2P**, 3-[[N-(3-Chlorophenyl)pyrrol-2-yl]methylene]-5-(acetylamino)indolin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [(phenylpyrrolyl)methylene]oxindoles as tubulin polymerization inhibitors for treatment of cancer)

RN 459143-84-1 CAPLUS
CN Acetamide, N-[3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 459143-85-2 CAPLUS
CN Acetamide, N-[3-[[1-(3-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.39     166.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.73      -0.73

FILE 'REGISTRY' ENTERED AT 10:16:40 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 APR 2005  HIGHEST RN 849400-77-7
DICTIONARY FILE UPDATES:  27 APR 2005  HIGHEST RN 849400-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10659094c.str
```



chain nodes :
10 11 23 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
3-25 7-10 8-11 10-12 13-17 25-26 25-28 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-16 13-14 14-15 15-16
17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
5-7 6-9 7-8 8-9 8-11 12-13 12-16 13-14 13-17 14-15 15-16 25-26 25-28
26-27
exact bonds :
3-25 7-10 10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 10:17:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    142 TO ITERATE

100.0% PROCESSED     142 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          2126 TO     3554
PROJECTED ANSWERS:                0 TO        0

L6             0 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 10:17:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   3592 TO ITERATE

100.0% PROCESSED    3592 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

L7             1 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.33     328.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.73

FILE 'CAPLUS' ENTERED AT 10:17:11 ON 28 APR 2005
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2005 VOL 142 ISS 18
FILE LAST UPDATED: 27 Apr 2005 (20050427/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7
L8 1 L7

=> d ibib abs hitstr tot

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:716271 CAPLUS
DOCUMENT NUMBER: 137:232554
TITLE: Compounds derived from oxindoles with activity as inhibitors of tubulin polymerization, and the use thereof in cancerology
INVENTOR(S): Combeau, Cecile; Mailliet, Patrick; Chiron, Marielle
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072575	A1	20020919	WO 2002-FR852	20020311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2822155	A1	20020920	FR 2001-3408	20010313
FR 2822155	B1	20031212		
EP 1370555	A1	20031217	EP 2002-722330	20020311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004082645	A1	20040429	US 2003-659094	20030910
PRIORITY APPLN. INFO.:			FR 2001-3408 A	20010313
			WO 2002-FR852 W	20020311

OTHER SOURCE(S): CASREACT 137:232554; MARPAT 137:232554
GI



I

AB The invention relates to compds. I [wherein: R5 = -NHCOR2 or -CONHR2; R2 =

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

C1-3 alkyl; X = Cl, Br; n = 1-3; exocyclic double bond is E, Z, or a mixt.]. I have antimitotic, antiproliferative, and antivascular properties by inhibition of the polymn. of tubulin into microtubules. Three specific compds. were prepd. in examples and claimed. For instance,

condensation of 5-(acetylamino)indolin-2-one with N-(3,5-dichlorophenyl)pyrrole-2-carboxaldehyde in the presence of piperidine in refluxing EtOH gave I [R5 = NHCOMe; (X)n = 3,5-dichloro] (II) in 40% yield. This compd. inhibited the polymn. of porcine cerebral tubulin in vitro with an IC50 of 2.4 μM. II also inhibited proliferation of HeLa cells in vitro with an IC50 of 0.05 μM, and induced detachment of HDMEC cells in vitro by 29% at 1 μM.

IT **459143-86-3P**, 3-[[N-(3,5-Dichlorophenyl)pyrrol-2-yl]methylene]-2-oxo-N-methylindoline-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [(phenylpyrrolyl)methylene]oxindoles as
tubulin polymerization inhibitors for treatment of cancer)

RN 459143-86-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAR 2005 HIGHEST RN 847735-80-2
DICTIONARY FILE UPDATES: 31 MAR 2005 HIGHEST RN 847735-80-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10659094.str



chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
7-10 8-11 10-12 13-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-16 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
5-7 6-9 7-8 8-9 8-11 12-13 12-16 13-14 13-17 14-15 15-16
exact bonds :
7-10 10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:23:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 243 TO 877
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:23:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 523 TO ITERATE

100.0% PROCESSED 523 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

L3 17 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 16:23:42 ON 01 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Apr 2005 VOL 142 ISS 15
FILE LAST UPDATED: 31 Mar 2005 (20050331/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 10 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:492716 CAPLUS
DOCUMENT NUMBER: 139:63316
TITLE: Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
INVENTOR(S): Masferrer, Jaime L.; Cherrington, Julie M.; Leahy, Kathleen M.; Zweifel, Ben S.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of Appl. No. PCT/US99/30693.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 21
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119895	A1	20030626	US 2002-150546	20020516
WO 2000038730	A2	20000706	WO 1999-US30693	19991222
WO 2000038730	A3	20001102		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2003097044	A1	20031127	WO 2003-US15582	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2003010027	A	20050215	BR 2003-10027	20030515
EP 1509224	A1	20050302	EP 2003-734058	20030515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:
US 1998-113786P P 19981223
WO 1999-US30693 A2 19991222
US 2002-150546 A 20020516
WO 2003-US15582 W 20030515

OTHER SOURCE(S): MARPAT 139:63316
AB The invention provides methods and compns. useful for treatment or prevention of neoplasia by administering a combination comprising a 3-heteroaryl-2-indolinone compound (preparation included) and a COX-2 selective inhibitor. Further provided are compns., pharmaceutical compns., and kits

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
for treatment and prevention of neoplasia.
IT 186611-35-8P, SU 5461 186611-36-9P, SU 5462
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heteroaryl indolinone-cyclooxygenase 2 inhibitor combination for treatment of neoplasia)
RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:716271 CAPLUS
DOCUMENT NUMBER: 137:232554
TITLE: Compounds derived from oxindoles with activity as inhibitors of tubulin polymerization, and the use thereof in cancerology
INVENTOR(S): Combeau, Cecile; Mailliet, Patrick; Chiron, Marielle
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072575	A1	20020919	WO 2002-FR852	20020311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2822155	A1	20020920	FR 2001-3408	20010313
FR 2822155	B1	20031212		
EP 1370555	A1	20031217	EP 2002-722330	20020311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004082645	A1	20040429	US 2003-659094	20030910

PRIORITY APPLN. INFO.:
FR 2001-3408 A 20010313
WO 2002-FR852 W 20020311

OTHER SOURCE(S): CASREACT 137:232554; MARPAT 137:232554
GI



I

AB The invention relates to compds. I [wherein: R5 = -NHCOR2 or -CONHR2; R2 =

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
C1-3 alkyl; X = Cl, Br; n = 1-3; exocyclic double bond is E, Z, or a mixt.]. I have antimitotic, antiproliferative, and antivascular properties by inhibition of the polymn. of tubulin into microtubules. Three specific compds. were prepd. in examples and claimed. For instance, condensation of 5-(acetylamino)indolin-2-one with N-(3,5-dichlorophenyl)pyrrole-2-carboxaldehyde in the presence of piperidine in refluxing EtOH gave I [R5 = NHCOMe; (X)n = 3,5-dichloro] (II) in 40% yield. This compd. inhibited the polymn. of porcine cerebral tubulin in vitro with an IC50 of 2.4 μM. II also inhibited proliferation of HeLa cells in vitro with an IC50 of 0.05 μM, and induced detachment of HDMEC cells in vitro by 29% at 1 μM.
IT 459143-84-1P, 3-[(N-(3,5-Dichlorophenyl)pyrrol-2-yl]methylene]-5-(acetylamino)indolin-2-one 459143-85-2P, 3-[[N-(3-Chlorophenyl)pyrrol-2-yl]methylene]-5-(acetylamino)indolin-2-one 459143-86-3P, 3-[[N-(3,5-Dichlorophenyl)pyrrol-2-yl]methylene]-2-oxo-N-methylindoline-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [(phenylpyrrolyl)methylene]oxindoles as tubulin polymerization inhibitors for treatment of cancer)
RN 459143-84-1 CAPLUS
CN Acetamide, N-[3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 459143-85-2 CAPLUS
CN Acetamide, N-[3-[[1-(3-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 459143-86-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:205317 CAPLUS
DOCUMENT NUMBER: 130:252240
TITLE: Preparation of 3-benzylidene-2-indolinones as tyrosine
kinase activity modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5886020	A	19990323	US 1996-655226	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
JP 10504323	T2	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
US 6846839	B1	20050125	US 1999-333703	19990616
US 2002102608	A1	20020801	US 2001-897755	20010703
US 2003069421	A1	20030410	US 2002-201593	20020724
US 6696448	B2	20040224		

PRIORITY APPLN. INFO.:

US 1995-485323	A2 19950607
EP 1996-918093	A3 19960605
JP 1997-501363	A3 19960605
US 1996-655223	A2 19960605
US 1996-655224	A2 19960605
US 1996-655226	A2 19960605
US 1996-655255	B2 19960605
US 1996-659191	A2 19960605
US 1996-702232	B2 19960823
US 1997-915366	A2 19970820
US 1998-75271	B1 19980508

OTHER SOURCE(S): MARPAT 130:252240
GI

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. [I; R1 = H or alkyl; R3 = ZR2; R2 = OR, NRaRb, 5-membered heteroaryl, etc.; R = H, alkyl, aryl; Ra,Rb = H, alkyl, COR; NRaRb = heterocyclyl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S; Z = (un)substituted 1,4-phenylene] were prepared Thus, 2-oxindole was condensed with PhCHO to give 3-benzylidene-2-indolinone. Data for biol. activity of I were given.

IT **186611-35-8P 186611-36-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-benzylidene-2-indolinones as tyrosine kinase activity modulators)

RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:193848 CAPLUS
DOCUMENT NUMBER: 130:237471
TITLE: 3-(2-Alkoxybenzylidene)-2-indolinones and their analogs for the treatment of disease
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 36 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5883116	A	19990316	US 1996-655224	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
JP 10504323	T2	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
US 6846839	B1	20050125	US 1999-333703	19990616
US 2002102608	A1	20020801	US 2001-897755	20010703

PRIORITY APPLN. INFO.:

US 1995-485323	A2	19950607
EP 1996-918093	A3	19960605
JP 1997-501363	A3	19960605
US 1996-655223	A2	19960605
US 1996-655224	A2	19960605
US 1996-655226	A2	19960605
US 1996-655255	B2	19960605
US 1996-659191	A2	19960605
US 1996-702232	B2	19960823
US 1997-915366	A2	19970820

OTHER SOURCE(S): MARPAT 130:237471
GI

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB Indolinones such as I were prepared for modulating tyrosine kinase signal transduction in order to regulate, modulate, and/or inhibit abnormal cell proliferation. Thus, a mixture of 134.0 mg oxindole, 151.4 mg 3-methyl-2-thiophenecarboxaldehyde, and 3 drops of piperidine in 2 mL EtOH was stirred at 90° for 3 h to give a 65% yield of I. In an ELISA assay to measure the inhibition of protein tyrosine kinase activity on the FLK-1 receptor, I showed an IC50 of 4.5 μM.
IT **186611-35-8P**, SU 5461 **186611-36-9P**, SU 5462
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(3-(2-alkoxybenzylidene)-2-indolinones and their analogs for modulating tyrosine kinase signal transduction)
RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:193846 CAPLUS
DOCUMENT NUMBER: 130:237470
TITLE: Preparation of 3-benzylidene-2-indolinones as tyrosine kinase activity modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 38 pp., Cont.-in-part of U.S. Ser. No. 485,233.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5883113	A	19990316	US 1996-659191	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
JP 10504323	T2	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
US 6225335	B1	20010501	US 1998-212494	19981215
US 6316635	B1	20011113	US 1999-293518	19990415
US 6846839	B1	20050125	US 1999-333703	19990616
US 2002102608	A1	20020801	US 2001-897755	20010703
US 2003176487	A1	20030918	US 2002-227550	20020826

PRIORITY APPLN. INFO.:

US 1995-485323	A2	19950607
EP 1996-918093	A3	19960605
JP 1997-501363	A3	19960605
US 1996-655223	A2	19960605
US 1996-655224	A2	19960605
US 1996-655226	A2	19960605
US 1996-655255	B2	19960605
US 1996-659191	A1	19960605
US 1996-702232	B2	19960823
US 1997-915366	A2	19970820
US 1998-82056P	P	19980416
US 1998-212494	A2	19981215
US 2001-765619	A3	20010122

OTHER SOURCE(S): MARPAT 130:237470

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
GI



I

AB Title compds. [I; R1 = H or alkyl; R3 = ZR2, 5-membered heteroaryl, etc.; R2 = OR, NRaRb, etc.; R = H, alkyl, aryl, etc.; Ra,Rb = H, alkyl, COR, etc.; NRaRb = heterocyclyl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S; Z = (un)substituted 1,4-phenylene] were prepared Thus, PhCHO was condensed with 2-oxindole to give I (R1 = R4-R7 = H, R3 = Ph, X = O). Data for biol. activity of I were given.

IT 186611-35-8P, SU 5461
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-benzylidene-2-indolinones as tyrosine kinase activity modulators)

RN 186611-35-8 CAPLUS

CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:747592 CAPLUS
DOCUMENT NUMBER: 130:3771
TITLE: Preparation of 3-(hetero)arylmethylidene-2-indolinone derivatives as modulators of protein kinase activity for use in treating cancer.
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Shawver, Laura Kay; Hirth, Klaus Peter
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850356	A1	19981112	WO 1998-US9017	19980507
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2289102	AA	19981112	CA 1998-2289102	19980507
AU 9876842	A1	19981127	AU 1998-76842	19980507
EP 984930	A1	20000315	EP 1998-924746	19980507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511852	T2	20020416	JP 1998-548319	19980507
US 6051593	A	20000418	US 1998-99721	19980619
US 6313158	B1	20011106	US 1998-100854	19980619
US 6133305	A	20001017	US 1998-161046	19980925
US 2001056094	A1	20011227	US 2000-482198	20000112
US 2001007033	A1	20010705	US 2000-516948	20000301
US 2002026053	A1	20020228	US 2001-916331	20010730
US 6506763	B2	20030114		
US 2002058661	A1	20020516	US 2001-948106	20010907
US 6696463	B2	20040224		
US 2002183370	A1	20021205	US 2001-29946	20011231
US 6579897	B2	20030617		
US 2004106630	A1	20040603	US 2003-725079	20031202
US 2004106618	A1	20040603	US 2003-725267	20031202

PRIORITY APPLN. INFO.:

US 1997-45838P	P	19970507
US 1997-46868P	P	19970508
US 1997-49324P	P	19970611
US 1997-50412P	P	19970620
US 1997-50413P	P	19970620
US 1997-50977P	P	19970620
US 1997-59336P	P	19970919
US 1997-59381P	P	19970919

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 1997-59384P	P	19970919
US 1997-59544P	P	19970919
US 1997-59677P	P	19970919
US 1997-59971P	P	19970925
US 1997-60194P	P	19970926
US 1998-74621	A3	19980507
WO 1998-US9017	W	19980507
US 1998-100854	A3	19980619
US 1998-99721	A1	19980619
US 1998-161046	A3	19980925
US 2000-482198	A3	20000112
US 2000-516948	B1	20000301
US 2001-819698	A3	20010329

OTHER SOURCE(S): MARPAT 130:3771
GI



I

AB Title compds. [I; A1-A4 = C, N; when any of A1-A4 = N, then the corresponding R3-R6 = null; R1 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclyl, trihalomethylcarbonyl, OH, CO2H, trihalomethylsulfonyl, etc.; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclyl, halo; R3-R6 = H, alkyl, trihalomethyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclyl, OH, SH, alkoxy, aryloxy, amino, phosphonyl, guanidinyl, NO2, halo, (iso)cyanato, etc.; R3R4 or R4R5 or R5R6 = cycloalkyl, aryl, heteroaryl, heteroalicyclyl, OCH2O, OCH2CH2O; Q = specified (substituted) (hetero)aryl; Z = O, S], were prepared Thus, 3-(4-imidazolylmethylidenyl)-4,6-dimethyl-2-indolinone inhibited CDK2 with IC50 = <0.78 μM.

IT 215537-55-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)

RN 215537-55-6 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:735056 CAPLUS
DOCUMENT NUMBER: 129:330650
TITLE: Preparation of 3-benzylidene-2-indolinones and analogs as tyrosine kinase signal transduction modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen Inc., USA
SOURCE: U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5834504	A	19981110	US 1996-655225	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
JP 10504323	T2	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605

PRIORITY APPLN. INFO.: US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605

OTHER SOURCE(S): MARPAT 129:330650
GI



I

AB Title compds. [I; R1 = H or alkyl; R2 = 2-halo-4-hydroxy- or -alkoxyphenyl, 4-hydroxy- or -alkoxyphenyl, 4-(di)(alkyl)aminophenyl, heteroaryl, etc.; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepared Thus, oxindole was condensed with 2-chloro-4-methoxybenzaldehyde to give I (R1 = R4-R7 = H, R2 = 2-chloro-4-methoxyphenyl, X = O). Data for biol. activity of I were given.
IT **186611-35-8P 186611-36-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-benzylidene-2-indolinones and analogs as tyrosine kinase signal transduction modulators)
RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 181 THERE ARE 181 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:542764 CAPLUS
DOCUMENT NUMBER: 129:175549
TITLE: Preparation of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 37 pp., Cont.-in-part of U. S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5792783	A	19980811	US 1996-655223	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
JP 10504323	T2	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
US 6316635	B1	20011113	US 1999-293518	19990415
US 6846839	B1	20050125	US 1999-333703	19990616
US 2002102608	A1	20020801	US 2001-897755	20010703

PRIORITY APPLN. INFO.: US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
US 1996-655223 A2 19960605
US 1996-655224 A2 19960605
US 1996-655226 A2 19960605
US 1996-655255 B2 19960605
US 1996-659191 A1 19960605
US 1996-702232 B2 19960823
US 1997-915366 A2 19970820
US 1998-82056P P 19980416
US 1998-212494 A2 19981215

OTHER SOURCE(S): MARPAT 129:175549
GI

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB Title compds. [I; R1 = H or alkyl; R2 = (un)substituted (hetero)aryl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepared Thus, oxindole was condensed with 4-pyridinecarboxaldehyde to give I (R1,R4-R7 = H, R2 = 4-pyridinyl, X = O). Data for biol. activity of I were given.
IT **186611-35-8P 186611-36-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators)
RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 179 THERE ARE 179 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:147306 CAPLUS
DOCUMENT NUMBER: 128:204803
TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth, Klaus
Peter; Shawver, Laura Kay; et al.
PATENT ASSIGNEE(S): Sugen, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon, Gerald
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807695	A1	19980226	WO 1997-US14736	19970820
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CN 1155838	A	19970730	CN 1996-190616	19960605
CA 2264220	AA	19980226	CA 1997-2264220	19970820
EP 929520	A1	19990721	EP 1997-939480	19970820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001503736	T2	20010321	JP 1998-510973	19970820
EP 1247803	A2	20021009	EP 2002-77564	19970820
EP 1247803	A3	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AU 9741556	A1	19980306	AU 1997-41556	19970821

PRIORITY APPLN. INFO.:

US 1996-702232	A	19960823
US 1996-31585P	P	19961205
US 1996-31586P	P	19961205
US 1996-31588P	P	19961205
US 1996-32546P	P	19961205
US 1996-32547P	P	19961205
US 1997-45565P	P	19970505
US 1997-45566P	P	19970505
US 1997-45714P	P	19970505
US 1997-45715P	P	19970505
US 1997-46843P	P	19970505

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

EP 1997-939480	A3	19970820
WO 1997-US14736	W	19970820

OTHER SOURCE(S): MARPAT 128:204803
GI



I

AB The invention relates to indolinone derivs. capable of modulating, regulating, and/or inhibiting protein kinase signal transduction. The compds. are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic diseases such as diabetes. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds., such as I, were prepared by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro.

IT **203993-71-9P**, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5,7-dibromo-2-indolinone **203993-80-0P**, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-iodo-2-indolinone **203993-89-9P**, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone **203993-98-0P**, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203994-07-4P**, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203994-16-5P**, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203994-25-6P**, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)

RN 203993-71-9 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203993-80-0 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203993-89-9 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

RN 203993-98-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203994-07-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203994-16-5 CAPLUS
CN Morpholine, 4-[[3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203994-25-6 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1997:140244 CAPLUS
DOCUMENT NUMBER: 126:139901
TITLE: Indolinone compounds capable of modulating tyrosine kinase signal transduction
INVENTOR(S): Tang, Peng Cho; Sun, Li; Mcmahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640116	A1	19961219	WO 1996-US8903	19960605
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
AU 9660441	A1	19961230	AU 1996-60441	19960605
AU 706597	B2	19990617		
EP 769947	A1	19970502	EP 1996-918093	19960605
EP 769947	B1	20010502		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9606410	A	19971230	BR 1996-6410	19960605
JP 10504323	T2	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
AT 200863	E	20010515	AT 1996-918093	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
NO 9605377	A	19970212	NO 1996-5377	19961213
HK 1011933	A1	20020118	HK 1998-113193	19981211
GR 3036315	T3	20011031	GR 2001-401166	20010731

PRIORITY APPLN. INFO.: US 1995-485323 A 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
WO 1996-US8903 W 19960605

OTHER SOURCE(S): MARPAT 126:139901

AB The present invention relates to organic mols. capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Representatives of the 5 different classes of compds. described are SU 4932 [3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone], SU 4312 [3-(4-dimethylaminobenzylidenyl)-2-indolinone], SU

5416 [3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone], SU 5204 [3-(2-ethoxybenzylidenyl)-2-indolinone], and SU 4942 [3-(4-bromobenzylidenyl)-2-indolinone]. Diseases which these compds. and their pharmaceutically acceptable prepns. may be effective against include arthritis, hepatic cirrhosis, diabetic nephropathy and psoriasis.

IT **186611-35-8P**, SU 5461 **186611-36-9P**, SU 5462
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolinones capable of modulating tyrosine kinase signal transduction)

RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)